Drugs / SPP635
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00561171 | Nov 2007 → Sep 2008 | essential hypertension, type 2 diabetes mellitus | Speedel Pharma Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00376636 | Oct 2006 → May 2007 | hypertensive disorder | Speedel Pharma Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPP635 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00376636 ↗ |
| Action | Inhibit | “oral renin inhibitor SPP635” NCT00376636 ↗ |
| Route | Oral | “novel oral renin inhibitor SPP635” NCT00376636 ↗ |